Related Experiment Videos
Tirofiban and intracoronary stenting: evaluation of a new pharmacologic regimen
T M Amidon1, J B Amidon, J M Benson
1Heart Institute of Puget Sound, 1035 116th Avenue N.E., Bellevue, WA 98004, USA.
Insights
Tirofiban infusion, a glycoprotein IIb/IIIa receptor antagonist, proved safe and effective as an adjunctive therapy for patients undergoing coronary stenting. This study found no deaths or urgent revascularizations in 50 patients, highlighting its potential in acute coronary syndromes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Glycoprotein IIb/IIIa receptor antagonists are established treatments for acute coronary syndromes.
- Abciximab has demonstrated efficacy in reducing cardiac morbidity in patients undergoing coronary stenting.
Purpose of the Study:
- To evaluate the safety and efficacy of tirofiban infusion as an adjunctive therapy during intracoronary stenting.
Main Methods:
- A prospective registry of 50 consecutive patients receiving tirofiban (12.5 mg) and coronary stenting was created.
- Follow-up was conducted for 30 days post-procedure.
Main Results:
- All 50 patients achieved successful stent deployment.
- The study reported 0% death, 0% urgent revascularization, 0% stroke, and 0% vascular injury.
- Rates of procedural infarct and bleeding complications were both 4%.
Conclusions:
- Tirofiban infusion appears to be a safe and effective adjunctive therapy in patients undergoing coronary stenting.
- The findings support the use of tirofiban in this patient population, warranting further investigation.
Abstract:
Glycoprotein IIb/IIIa receptor antagonists are effective in decreasing cardiac events in patients with acute coronary syndromes. Abciximab reduces cardiac morbidity in patients receiving coronary stents. We sought to evaluate the use of tirofiban infusion in patients receiving intracoronary stents. We created a prospective registry of 50 consecutive patients in a single catheterization lab receiving a single vial of tirofiban (12.5 mg) and stenting. Successful stent deployment with a 30-day follow-up occurred in all patients. Clinical endpoints included death (0%), procedural infarct (4%), urgent revascularization (0%), stroke (0%), bleeding complication (4%), and vascular injury (0%). Tirofiban appeared to be a safe adjunctive therapy to coronary stenting.